Velzatinib

Small molecule

Also known as GSK6042981

Phase 3underway

Evidence outlook · registrational

Gastrointestinal Stromal Tumor: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2028-05-30.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Gastrointestinal Stromal Tumor
NCT07218926 · GlaxoSmithKline
2025-12-03 – 2030-11-29 · Gastrointestinal Neoplasms
What this study did
Phase 2 (2)
Gastrointestinal Stromal Tumor
NCT07843641 · GlaxoSmithKline
2026-10-13 – 2031-01-31 · Gastrointestinal Neoplasms
What this study did
Other / comorbidity
NCT07689201 · GlaxoSmithKline
2026-08-17 – 2029-08-17 · Gastrointestinal Neoplasms
What this study did
Phase 1 (3)
Other / comorbidity
NCT07859735 · GlaxoSmithKline
2026-11-10 – 2028-04-25 · Healthy Participants, Gastrointestinal Neoplasms
What this study did
NCT07867171 · GlaxoSmithKline
2026-10-23 – 2027-09-09 · Healthy Participants, Gastrointestinal Neoplasms
What this study did
NCT07862114 · GlaxoSmithKline
2026-10-16 – 2027-01-12 · Healthy Participants, Gastrointestinal Neoplasms
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Gastrointestinal Stromal Tumor: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Velzatinib: this drugPhase 3Small moleculeKITnot yet gradedNo reviewed efficacy summary in this indication
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)not yet gradedNo reviewed efficacy summary in this indication
Barzolvolimab
Phase 3(overall)
Monoclonal antibodyKIT
Partial signal(overall)
No reviewed efficacy summary in this indication
BezuclastinibPhase 3Small moleculeKITnot yet gradedNo reviewed efficacy summary in this indication
Briquilimab
Phase 1/2(overall)
Monoclonal antibodyKIT
Partial signal(overall)
No reviewed efficacy summary in this indication
SAR449028
—(overall)
UndisclosedKIT
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Velzatinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
January 2027 (1)
Phase 1Healthy Participants, Gastrointestinal NeoplasmsNot yet recruiting
Est. primary completion 2027-01-12 · NCT07862114 · CT.gov ↗
What to watch
September 2027 (1)
Phase 1Healthy Participants, Gastrointestinal NeoplasmsNot yet recruiting
Est. primary completion 2027-09-09 · NCT07867171 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Gastrointestinal NeoplasmsRecruiting
Est. primary completion 2027-11-29 · NCT07689201 · CT.gov ↗
What to watch
2028 (2)
April 2028 (1)
Phase 1Healthy Participants, Gastrointestinal NeoplasmsNot yet recruiting
Est. primary completion 2028-04-25 · NCT07859735 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Gastrointestinal Stromal TumorRecruiting
Est. primary completion 2028-05-30 · NCT07218926 · CT.gov ↗
What to watch
2031 (1)
January 2031 (1)
Phase 2Gastrointestinal Stromal TumorNot yet recruiting
Est. primary completion 2031-01-31 · NCT07843641 · CT.gov ↗
What to watch
2032 (1)
August 2032 (1)
Phase 3Gastrointestinal Stromal TumorRecruiting
Est. primary completion 2032-08-30 · NCT07585266 · CT.gov ↗
What to watch

See the full readout calendar ↗